International trade · 12/04/2010

U.S. International Trade Commission Grants Amgen Inc.'s Motion to Terminate Investigation

The U.S. International Trade Commission has decided to partially terminate an investigation into certain products and pharmaceutical compositions containing recombinant human erythropoietin, following a motion by Amgen Inc. The Commission is now seeking input on how to address issues related to the investigation's outcome and the public interest.